Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease

被引:37
|
作者
Schlaudraff, Falk [1 ]
Grundemann, Jan [2 ]
Fauler, Michael [1 ]
Dragicevic, Elena [1 ]
Hardy, John [3 ,4 ]
Liss, Birgit [1 ]
机构
[1] Univ Ulm, Inst Appl Physiol, Dept Appl Physiol, D-89081 Ulm, Germany
[2] Friedrich Miescher Inst Biomed Res, Basel, Switzerland
[3] Inst Neurol, Dept Mol Neurosci, London, England
[4] Inst Neurol, Reta Lila Weston Labs, London, England
关键词
SNCA140; PARK; RIN; Mixed-effects-model; miR-133b; NURR1; PITX3; UV-LMD; UCHL-1; ATPase13A2; Parkin; LRRK2; ALPHA-SYNUCLEIN EXPRESSION; GENE-EXPRESSION; SUBSTANTIA-NIGRA; NEUROTROPHIC FACTOR; HUMAN BRAIN; STEM-CELLS; OVEREXPRESSION; NEURODEGENERATION; IDENTIFICATION; CONSEQUENCES;
D O I
10.1016/j.neurobiolaging.2014.03.016
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Progressive loss of substantia nigra dopamine neurons (SN DA) is a hallmark of aging and of Parkinson's disease (PD). Mutations in PARK genes cause familial PD forms. Increased expression of alpha-synuclein (PARK4) is a disease-triggering event in familial PD and also observed in SN DA neurons in sporadic PD but related transcriptional changes are unknown. With optimized single-cell quantitative real-time polymerase chain reaction analysis, we compared messenger RNA and microRNA levels in SN DA neurons from sporadic PD patients and controls. Non-optimally matched donor ages and RNA integrities are common problems when analyzing human samples. We dissected the influence of distinct ages and RNA integrities of our samples by applying a specifically-optimized, linear-mixed-effects model to quantitative real-time polymerase chain reaction-data. We identified that elevated alpha-synuclein messenger RNA levels in SN DA neurons of human PD brains were positively correlated with corresponding elevated levels of mRNAs for functional compensation of progressive SN DA loss and for enhanced proteasomal (PARK5/UCHL1) and lysosomal (PARK9/ATPase13A2) function, possibly counteracting alpha-synuclein toxicity. In contrast, microRNA miR-133b levels, previously implicated in transcriptional dysregulation in PD, were not altered in SN DA neurons in PD. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2302 / 2315
页数:14
相关论文
共 50 条
  • [1] Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson's Disease
    Zhang, Xiong
    Yang, Rui
    Hu, Bei-Lei
    Lu, Pengcheng
    Zhou, Li-Li
    He, Zhi-Yong
    Wu, Hong-Mei
    Zhu, Jian-Hong
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2017, 11
  • [2] Dopamine neurons exhibit emergent glutamatergic identity in Parkinson's disease
    Steinkellner, Thomas
    Conrad, William S.
    Kovacs, Imre
    Rissman, Robert A.
    Lee, Edward B.
    Trojanowski, John Q.
    Freyberg, Zachary
    Roy, Subhojit
    Luk, Kelvin C.
    Lee, Virginia M.
    Hnasko, Thomas S.
    BRAIN, 2022, 145 (03) : 879 - 886
  • [3] Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease
    Reyes, Stefanie
    Fu, Yuhong
    Double, Kay L.
    Cottam, Veronica
    Thompson, Lachlan H.
    Kirik, Deniz
    Paxinos, George
    Watson, Charles
    Cooper, Helen M.
    Halliday, Glenda M.
    NEUROBIOLOGY OF AGING, 2013, 34 (03) : 873 - 886
  • [4] Replacing Dopamine Neurons in Parkinson's Disease: How did it happen?
    Bjorklund, Anders
    Lindvall, Olle
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 : S23 - S33
  • [5] Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons
    Kim, Hyun-Jung
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (01): : 1 - 11
  • [6] Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease
    Ledonne, Ada
    Cenere, Mariangela Massaro
    Paldino, Emanuela
    D'Angelo, Vincenza
    D'Addario, Sebastian Luca
    Casadei, Nicolas
    Nobili, Annalisa
    Berretta, Nicola
    Fusco, Francesca R.
    Ventura, Rossella
    Sancesario, Giuseppe
    Guatteo, Ezia
    Mercuri, Nicola Biagio
    MOVEMENT DISORDERS, 2023, 38 (02) : 256 - 266
  • [7] Dopamine in Parkinson's disease
    Latif, Saad
    Jahangeer, Muhammad
    Razia, Dure Maknoon
    Ashiq, Mehvish
    Ghaffar, Abdul
    Akram, Muhammad
    El Allam, Aicha
    Bouyahya, Abdelhakim
    Garipova, Larisa
    Shariati, Mohammad Ali
    Thiruvengadam, Muthu
    Ansari, Mohammad Azam
    CLINICA CHIMICA ACTA, 2021, 522 : 114 - 126
  • [8] The Role of Transcription Factor Pitx3 in Dopamine Neuron Development and Parkinson's Disease
    Li, Jia
    Dani, John A.
    Le, Weidong
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 855 - 859
  • [9] SERUM MIR-9A AND MIR-133B, DIAGNOSTIC MARKERS FOR PARKINSON'S DISEASE, ARE UP-REGULATED AFTER LEVODOPA TREATMENT
    Wu, Lin
    Zha, Weiai
    Kong, Fanbin
    Yang, Fang
    Zheng, Jiaping
    ACTA MEDICA MEDITERRANEA, 2020, 36 (03): : 1857 - 1863
  • [10] Kir6.2 Deficiency Promotes Mesencephalic Neural Precursor Cell Differentiation via Regulating miR-133b/GDNF in a Parkinson's Disease Mouse Model
    Zhou, Yan
    Zhu, Jialei
    Lv, Yang
    Song, Chenghuan
    Ding, Jianhua
    Xiao, Ming
    Lu, Ming
    Hu, Gang
    MOLECULAR NEUROBIOLOGY, 2018, 55 (11) : 8550 - 8562